沿迷走神经、膈神经行肺门纵隔淋巴结清扫在非小细胞肺癌(NSCLC)根治术中的应用研究

注册号:

Registration number:

ChiCTR1800018837 

最近更新日期:

Date of Last Refreshed on:

2018-10-12 23:50:05 

注册时间:

Date of Registration:

2018-10-12 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

沿迷走神经、膈神经行肺门纵隔淋巴结清扫在非小细胞肺癌(NSCLC)根治术中的应用研究

Public title:

The application of the strategy along vagus nerve and phrenic nerve chain in the systematic lymph node dissection for NSCLC patients

注册题目简写:

English Acronym:

研究课题的正式科学名称:

沿迷走神经、膈神经行肺门纵隔淋巴结清扫在非小细胞肺癌(NSCLC)根治术中的应用研究

Scientific title:

The application of the strategy along vagus nerve and phrenic nerve chain in the systematic lymph node dissection for NSCLC patients

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

刘振国 

研究负责人:

程超 

Applicant:

Liu Zhenguo 

Study leader:

Cheng Chao 

申请注册联系人电话:

Applicant telephone:

+86 13570323215

研究负责人电话:

Study leader's
telephone:

+86 13710763975

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

liuzg1340@126.com

研究负责人电子邮件:

Study leader's E-mail:

drchengchao@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

广东省广州市越秀区中山二路58号中山大学附属第一医院

研究负责人通讯地址:

广东省广州市越秀区中山二路58号中山大学附属第一医院

Applicant address:

58 Second Zhongshan Road, Guangzhou, Guangdong, China

Study leader's address:

58 Second Zhongshan Road, Guangzhou, Guangdong, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

中山大学附属第一医院

Applicant's institution:

The First Affiliated Hospital of Sun Yat-sen University

研究负责人所在单位:

中山大学附属第一医院

Affiliation of the Leader:

The First Affiliated Hospital of Sun Yat-sen University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

A2018-006

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

广东省胸部肿瘤防治研究会

Name of the ethic committee:

GASTO

伦理委员会批准日期:

Date of approved by ethic committee:

1990-01-01 00:00:00

伦理委员会联系人:

王思愚

Contact Name of the ethic committee:

Wang Siyu

伦理委员会联系地址:

广东省广州市越秀区先烈南路9号

Contact Address of the ethic committee:

9 South Xianlie Road, Yuexiu District, Guangzhou, Guangdong, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

中山大学附属第一医院

Primary sponsor:

The First Affiliated Hospital of Sun Yat-sen University

研究实施负责(组长)单位地址:

广东省广州市越秀区中山二路58号中山大学附属第一医院

Primary sponsor's address:

58 Second Zhongshan Road, Guangzhou, Guangdong, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广东

市(区县):

广州

Country:

China

Province:

Guangdong

City:

Guangzhou

单位(医院):

中山大学附属第一医院

具体地址:

广东省广州市越秀区中山二路58号中山大学附属第一医院

Institution
hospital:

The First Affiliated Hospital of Sun Yat-sen University

Address:

58 Second Zhongshan Road, Guangzhou, Guangdong, China

经费或物资来源:

研究者资助

Source(s) of funding:

Investigator-sponsored

研究疾病:

非小细胞肺癌  

Target disease:

NSCLC

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

治疗新技术临床试验 

Study phase:

New Treatment Measure Clinical Study

研究设计:

历史对照研究 

Study design:

Historical control 

研究目的:

通过收集行非小细胞肺癌(NSCLC)根治术时采用“沿迷走神经、膈神经清扫肺门纵隔淋巴结”的患者的临床资料,评估该淋巴结清扫方式的术式安全性、淋巴结清扫彻底性及临床疗效。  

Objectives of Study:

Collecting the clinical data of patients who underwent radical resection with the new strategy for systematic lymph node dissection along the vagus nerve and phrenic nerve chain of non-small cell lung cancer (NSCLC) to evaluate surgical safety, the degree of lymph node dissection and clinical efficacy.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1.在本研究之前的五年内患有除 NSCLC 以外的其它癌症;
2.已知的人类免疫缺陷病毒(HIV)感染;
3.混有小细胞肺癌成份的患者;
4.怀孕或哺乳期妇女;
5.既往有明确的神经或精神障碍史,包括癫痫或痴呆;
6.术前接受新辅助放化疗;
7.其他研究者认为不适合入组的情况。

Exclusion criteria:

1. Have cancer other than NSCLC within five years prior to the study;
2. Known human immunodeficiency virus (HIV) infection;
3. With small cell lung cancer components;
4. Pregnant or lactating women;
5. Have a clear history of neurological or mental disorders, including epilepsy or dementia;
6. neoadjuvant chemoradiation before surgery;
7. Other situations investigators believe that it is not suitable for enrollment.

研究实施时间:

Study execute time:

From 2018-10-13 00:00:00 To 2020-10-13 00:00:00  

征募观察对象时间:

Recruiting time:

From 2018-10-13 00:00:00 To 2019-10-13 00:00:00

干预措施:

Interventions:

组别:

新术式组

样本量:

60

Group:

Case series

Sample size:

干预措施:

肺癌根治术时沿迷走神经膈神经行系统性淋巴结清扫

干预措施代码:

Intervention:

radical surgery of lung cancer with the strategy along the vagus nerve and phrenic nerve chain in systemic lymph node dissection

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

广东 

市(区县):

广州 

Country:

China

Province:

Guangdong

City:

单位(医院):

中山大学附属第一医院 

单位级别:

三甲 

Institution
hospital:

The First Affiliated Hospital of Sun Yat-sen University

Level of the institution:

Tertiary A Hospital

测量指标:

Outcomes:

指标中文名:

术后病理N分期上调率

指标类型:

主要指标

Outcome:

postoperative pathological N-stage up-regulation rate

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后生存质量

指标类型:

主要指标

Outcome:

postoperative quality of life

Type:

Primary indicator

测量时间点:

术后3个月时

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

迷走神经损伤评分

指标类型:

次要指标

Outcome:

Vagus nerve injury score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

膈神经损伤评分

指标类型:

次要指标

Outcome:

Phrenic nerve injury score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

淋巴结清扫组数

指标类型:

次要指标

Outcome:

the number of lymph node dissection groups

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

总生存期

指标类型:

次要指标

Outcome:

OS

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

无疾病生存期

指标类型:

次要指标

Outcome:

DFS

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

围术期并发症

指标类型:

次要指标

Outcome:

Perioperative complications

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

淋巴结清扫个数

指标类型:

次要指标

Outcome:

the number of dissected lymph nodes

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

肿瘤组织

组织:

Sample Name:

tumor

Tissue:

人体标本去向

使用后保存  

说明

Fate of sample:

Preservation after use  

Note:

标本中文名:

淋巴结

组织:

Sample Name:

lymph node

Tissue:

人体标本去向

使用后保存  

说明

Fate of sample:

Preservation after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 75 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

该研究为单臂研究,无需随机处理

Randomization Procedure (please state who generates the random number sequence and by what method):

The study is a single arm study without random processing.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

未说明

Blinding:

Not stated

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

采用Chictr.org.cn网络平台公开

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

open the IPD on Chictr.org.cn

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据通过CRF表格记录,并由课题研究人员负责管理

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

the primary data were collected on Case-Report Form(CRF), which will be saved and managed by a researcher

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2018-10-12 23:50:05